Biotech Analyst Blum, along with Dr. Santoro, Associate Professor of Neurology and Pediatrics at the Keck School of Medicine at USC, discuss the therapeutic landscape for Myasthenia Gravis (MG) and focus on recent clinical results from Cartesian Therapeutics (RNAC)’ Descartes-08 on an Analyst/Industry conference call to be held on December 2 at 11 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian to present updated data from Phase 2b trial of Descartes-08
- Cartesian Therapeutics Reports Q3 2024 Financial Results
- Cartesian Therapeutics announces employment inducement grant
- Cartesian Therapeutics price target lowered to $41 from $45 at H.C. Wainwright
- Cartesian Therapeutics reports Q3 EPS ($1.13) , consensus (79c)